A Science & Innovation Webinar, presented by Pfizer. 

This presentation will discuss LITFULO, ritlecitinib, indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. The program will provide a brief overview of the disease state, consider appropriate patients for oral treatment, review LITFULO’s efficacy and safety profile, and discuss initiation and monitoring of LITFULO.

The invite-only webinar aims to enhance the upcoming AMCP Foundation Research Symposium. Gain invaluable insights with virtual breakout sessions, laying the foundation for impactful face-to-face discussions and networking prospects.

An AMCP Market Insights Webinar. 

Join our upcoming Market Insights webinar to explore the latest practice recommendations in the management and treatment of food allergies. Attendees will gain insights from in-depth expert interviews and survey findings from managed care professionals, identifying best practices for coverage, access, and clinical management. A peer-to-peer panel discussion will feature selected managed care leaders who will delve into applying these best practices within health plans, offering actionable strategies to improve patient outcomes.

A Pre-Approval Information Exchange (PIE) Webinar, presented by LEO Pharma.

Delgocitinib is an investigational treatment currently being evaluated for Chronic Hand Eczema (CHE). This pre-approval information exchange (PIE) presentation provides an overview of disease state (including etiologic subtypes), unmet needs in CHE and the delgocitinib MOA and pivotal trial data.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie.

Major Depressive Disorder (MDD) is a disabling mental health condition with an annual prevalence of 10.4% and a lifetime prevalence of 20.6% in the US. This is associated with a high economic burden, which has increased significantly over the last decade, comprising direct and indirect costs, due to lost productivity. MDD also results in considerable burden to patients, with social, emotional and physical problems; cognitive difficulties; changes in sleep and eating patterns; and can impact patients’ quality of life.  Many MDD patients require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate MDD patients. This session will focus on the burden of MDD, as well as the pharmacology, efficacy, and safety of an adjunctive treatment for MDD.